依那沙普林用于携带两种载脂蛋白L1变体的人群的蛋白尿性肾病。回复。 - Suppr

Suppr

超能文献

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.

作者信息

Egbuna Ogo, Chertow Glenn M

机构信息

Vertex Pharmaceuticals, Boston, MA

Stanford University School of Medicine, Palo Alto, CA.

出版信息

N Engl J Med. 2023 Jun 29;388(26):2491. doi: 10.1056/NEJMc2304780.

DOI:10.1056/NEJMc2304780

PMID:37379148

Abstract

摘要

相似文献

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.

N Engl J Med. 2023 Jun 29;388(26):2491. doi: 10.1056/NEJMc2304780.

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.

N Engl J Med. 2023 Jun 29;388(26):2490. doi: 10.1056/NEJMc2304780.

Inaxaplin for Proteinuric Kidney Disease in Persons with Two Variants.

N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396.

Inaxaplin for the treatment of APOL1-associated kidney disease.

Nat Rev Nephrol. 2023 Aug;19(8):479-480. doi: 10.1038/s41581-023-00721-0.

APOL1 Nephropathy: From Genetics to Clinical Applications.

Clin J Am Soc Nephrol. 2021 Feb 8;16(2):294-303. doi: 10.2215/CJN.15161219. Epub 2020 Jul 2.

Introduction: APOL1-Associated Kidney Disease.

Semin Nephrol. 2017 Nov;37(6):489. doi: 10.1016/j.semnephrol.2017.07.001.

Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Kidney Int. 2019 Dec;96(6):1303-1307. doi: 10.1016/j.kint.2019.07.010. Epub 2019 Aug 1.

The Relationship between APOL1 Structure and Function: Clinical Implications.

Kidney360. 2020 Nov 4;2(1):134-140. doi: 10.34067/KID.0002482020. eCollection 2021 Jan 28.

Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.

Glomerular Dis. 2024 Mar 14;4(1):64-73. doi: 10.1159/000538255. eCollection 2024 Jan-Dec.

Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

J Am Soc Nephrol. 2019 Oct;30(10):2027-2036. doi: 10.1681/ASN.2019030240. Epub 2019 Aug 5.

引用本文的文献

Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.

Am J Hematol. 2025 Jun;100(6):1019-1028. doi: 10.1002/ajh.27678. Epub 2025 Apr 5.

Surrogate Clinical End Points in Studies of APOL1-Associated Kidney Disease: Just in Time.

Clin J Am Soc Nephrol. 2025 Jan 1;20(1):3-5. doi: 10.2215/CJN.0000000628. Epub 2024 Dec 16.

Pathogenesis of HIV-associated nephropathy in children and adolescents: taking a hard look 40 years later in the era of gene-environment interactions.

Am J Physiol Renal Physiol. 2024 Dec 1;327(6):F1049-F1066. doi: 10.1152/ajprenal.00208.2024. Epub 2024 Sep 26.

In Search of the Mechanism of APOL1 Kidney Disease.

J Am Soc Nephrol. 2024 Jun 1;35(6):815-817. doi: 10.1681/ASN.0000000000000368. Epub 2024 Apr 10.

Defining Risk in APOL1-Associated Kidney Disease: The Story is Evolving!

Am J Kidney Dis. 2024 Sep;84(3):388-391. doi: 10.1053/j.ajkd.2024.03.016. Epub 2024 Apr 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.

N Engl J Med. 2023 Jun 29;388(26):2491. doi: 10.1056/NEJMc2304780.

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.

N Engl J Med. 2023 Jun 29;388(26):2490. doi: 10.1056/NEJMc2304780.

Inaxaplin for Proteinuric Kidney Disease in Persons with Two Variants.

N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396.

Inaxaplin for the treatment of APOL1-associated kidney disease.

Nat Rev Nephrol. 2023 Aug;19(8):479-480. doi: 10.1038/s41581-023-00721-0.

APOL1 Nephropathy: From Genetics to Clinical Applications.

Clin J Am Soc Nephrol. 2021 Feb 8;16(2):294-303. doi: 10.2215/CJN.15161219. Epub 2020 Jul 2.

Introduction: APOL1-Associated Kidney Disease.

Semin Nephrol. 2017 Nov;37(6):489. doi: 10.1016/j.semnephrol.2017.07.001.

Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Kidney Int. 2019 Dec;96(6):1303-1307. doi: 10.1016/j.kint.2019.07.010. Epub 2019 Aug 1.

The Relationship between APOL1 Structure and Function: Clinical Implications.

Kidney360. 2020 Nov 4;2(1):134-140. doi: 10.34067/KID.0002482020. eCollection 2021 Jan 28.

Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.

Glomerular Dis. 2024 Mar 14;4(1):64-73. doi: 10.1159/000538255. eCollection 2024 Jan-Dec.

Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

J Am Soc Nephrol. 2019 Oct;30(10):2027-2036. doi: 10.1681/ASN.2019030240. Epub 2019 Aug 5.

引用本文的文献

Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.

Am J Hematol. 2025 Jun;100(6):1019-1028. doi: 10.1002/ajh.27678. Epub 2025 Apr 5.

Surrogate Clinical End Points in Studies of APOL1-Associated Kidney Disease: Just in Time.

Clin J Am Soc Nephrol. 2025 Jan 1;20(1):3-5. doi: 10.2215/CJN.0000000628. Epub 2024 Dec 16.

Pathogenesis of HIV-associated nephropathy in children and adolescents: taking a hard look 40 years later in the era of gene-environment interactions.

Am J Physiol Renal Physiol. 2024 Dec 1;327(6):F1049-F1066. doi: 10.1152/ajprenal.00208.2024. Epub 2024 Sep 26.

In Search of the Mechanism of APOL1 Kidney Disease.

J Am Soc Nephrol. 2024 Jun 1;35(6):815-817. doi: 10.1681/ASN.0000000000000368. Epub 2024 Apr 10.

Defining Risk in APOL1-Associated Kidney Disease: The Story is Evolving!

Am J Kidney Dis. 2024 Sep;84(3):388-391. doi: 10.1053/j.ajkd.2024.03.016. Epub 2024 Apr 20.